Validus Cellular Therapeutics is at the forefront of developing innovative cellular therapies aimed at treating bacterial infections, particularly those that have become resistant to traditional antibiotic treatments. The company focuses on harnessing the potential of mesenchymal stromal cells (MSCs), which are precursor cells that play a crucial role in the body's immune response. Validus has discovered a method to pre-activate these MSCs, enabling them to effectively migrate to sites of infection. Once there, the activated MSCs release natural antimicrobial peptides and cytokines that not only help to eliminate bacteria but also recruit professional immune cells, such as phagocytes, to enhance the body's healing process.

The lead product from Validus is an allogeneic cell therapy delivered via intravenous infusion, which is set to enter clinical trials soon. This therapy aims to address the limitations of unactivated MSCs, which have previously struggled to locate and respond to infections. By activating the MSCs, Validus enhances their ability to recruit immune cells, particularly M2 macrophages that are essential for tissue repair, thereby improving the overall clearance of infections. This pioneering approach represents a significant advancement in the field of antibacterial therapy, offering a promising alternative to conventional antibiotics that are increasingly becoming ineffective against resistant bacterial strains.

United States

For patients and doctors battling chronic resistant infections, Validus Cellular Therapeutics is developing VCT-101, a novel preclinical stage anti-infective therapy unlike current small molecule antibiotics which are susceptible to resistance and are limited accessing infections. VCT-101 is a cell therapy to be given with standard of care antibiotic regimens to successfully treat of chronic infections through direct bacterial killing and immune system boosting mechanisms.

Validus Cellular Therapeutics

Company Details